Our research focusses on the role of the microbiome and diet in inflammatory bowel disease (IBD) and other gut disorders and manipulating the microbiome and diet for therapeutic effect.

We have demonstrated that faecal microbiota transplantation can safely induce remission of active ulcerative colitis but that the clinical effect diminishes with time. This provides evidence that this new therapy is both effective and practical in terms of delivery for patients. It is a therapeutic option for patients that does not result in immune suppression that many current therapies do. We have also established a not for profit organisation “BiomeBank” with The Hospital Research Foundation (THRF) that will run the stool bank that is also used to treat South Australian patients with recurrent Clostridium difficile infection.